TransMedics Group, Inc. - Common Stock (TMDX)

TransMedics continues to lock in its status as the leader in organ transplant technology.

TransMedics Group shares are rising in Wednesday's after-hours session after the company reported financial results for the second quarter.

TransMedics reported second-quarter financial results that were considerably better than most investors had anticipated. Investors were also pleased that TransMedics increased its guidance for the full 2025 year.

TRANSMEDICS (TMDX) shows strong earnings momentum with 500% EPS growth and a solid technical setup, making it a candidate for high-growth investors.

TransMedics Group and two other mid-cap names just posted dominant performances in Q1, smashing forecasts set by Wall Street analysts.

Three med-tech stocks, TransMedics, Insulet, and GRAIL, are outperforming the market and their sector while forming bullish technical patterns.

These three small stocks carry significant risk, but that volatility has served traders well this year; now it's time for long-term investors to take a look

TRANSMEDICS (TMDX) shows strong earnings growth and improving margins while presenting a favorable technical setup, making it interesting for momentum investors.

The company is an expert in getting donated livers, hearts and lungs to transplant recipients.